Komori

Materials for the Results Briefing for the Second Quarter of the Fiscal Year Ending March 2027

Results presentationFirst half, FY ending Mar 2027Published 2026-11-17 15:30

For the cumulative second quarter, revenue decreased year on year, while the operating loss, ordinary loss and net loss all widened. Business development in drug discovery and antibody technologies, including the joint research agreement with KYORIN Pharmaceutical Co.,Ltd., also progressed.

In short

  • Revenue decreased from ¥60 million in the same period of the previous year to ¥52 million.
  • The net loss widened by ¥20 million year on year to ¥399 million.
  • The company entered into a joint research agreement with KYORIN Pharmaceutical Co.,Ltd. to pursue the creation of novel antibody medicines.

What they reported

this period against the same period a year earlier, and where they now expect the year to end

Sales

¥52.0m−13.3%vs a year earlier
H1 FY26¥60.0mH1 FY27¥52.0m
FY25FY26FY27 · this year203040¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4+52%−54%this yearvs same quarter last yearlast year
Sales by quarter
Period¥m
FY25 Q120.0
FY25 Q239.0
FY25 Q324.0
FY25 Q437.0
FY26 Q123.0
FY26 Q237.0
FY26 Q343.0
FY26 Q432.0
FY27 Q135.0
FY27 Q217.0
Why

Revenue decreased year on year.

売上高:前年同期比約13.7%減
Revenue: down approximately 13.7% year on year

Operating profit

−¥411.0mloss widenedvs a year earlier
H1 FY26−¥399.0mH1 FY27−¥411.0m
FY25FY26FY27 · this year-220-200-180¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▲▼this yearvs same quarter last yearlast year
Operating profit by quarter
Period¥m
FY25 Q1-221.0
FY25 Q2-193.0
FY25 Q3-216.0
FY25 Q4-196.0
FY26 Q1-218.0
FY26 Q2-181.0
FY26 Q3-174.0
FY26 Q4-171.0
FY27 Q1-204.0
FY27 Q2-207.0

Ordinary profit

−¥394.0mloss widenedvs a year earlier
H1 FY26−¥345.0mH1 FY27−¥394.0m
FY25FY26FY27 · this year-220-200-180-160¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼this yearvs same quarter last yearlast year
Ordinary profit by quarter
Period¥m
FY25 Q1-214.0
FY25 Q2-213.0
FY25 Q3-197.0
FY25 Q4-205.0
FY26 Q1-171.0
FY26 Q2-174.0
FY26 Q3-164.0
FY26 Q4-169.0
FY27 Q1-201.0
FY27 Q2-193.0

Net profit

−¥399.0mloss widenedvs a year earlier
H1 FY26−¥379.0mH1 FY27−¥399.0m
FY25FY26FY27 · this year-250-200-150¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼▲this yearvs same quarter last yearlast year
Net profit by quarter
Period¥m
FY25 Q1-219.0
FY25 Q2-276.0
FY25 Q3-199.0
FY25 Q4-210.0
FY26 Q1-176.0
FY26 Q2-203.0
FY26 Q3-168.0
FY26 Q4-171.0
FY27 Q1-202.0
FY27 Q2-197.0
Why

The net loss widened due to lower revenue and a decrease in subsidies.

純利益:売上減影響及び助成金減により前年同期比20百万円損失増
Net income: the impact of lower revenue and a decrease in subsidies resulted in a ¥20 million increase in the loss year on year

Their own numbers

figures this company chose to report, a year ago against now
Number of clinical trial sites
10 Medical institutions

A physician-initiated clinical trial of PPMX-T003 is being conducted at 10 medical institutions nationwide.

The low–high ranges are Komori's estimate, not figures the company gave.

Everything else in the deck

New initiatives

what they said they're starting
  • The company entered into a joint research agreement with KYORIN Pharmaceutical Co.,Ltd. to pursue the creation of novel antibody medicines.
  • The company advanced its joint research with Eurus Therapeutics Co., Ltd. and entered into a new agreement.

What decks usually leave out

COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deck

Margins and overheads

where each ¥100 of sales goes
Computed
a year ago-665.0%now-790.4%

Overheads (selling and admin costs): ¥458.0m

Financial targets

the last five years against the target (green band), where one is stated
Computed
Return on equity-54.2%
profit earned on shareholders' money
+9.7 pts on last year
-66%-46%-26%FY23FY24FY25FY26FY23: -28.3%FY24: -58.2%FY25: -63.9%FY26: -54.2%-54.2%
Return on equity
Period%
FY23-28.3
FY24-58.2
FY25-63.9
FY26-54.2
Equity ratio62.7%
how much of the balance sheet is owned outright
−7.4 pts on last year
61%79%97%FY22FY23FY24FY25FY26FY27FY22: 95.5%FY23: 92.1%FY24: 78.2%FY25: 74.4%FY26: 70.1%FY27: 62.7%62.7%
Equity ratio
Period%
FY2295.5
FY2392.1
FY2478.2
FY2574.4
FY2670.1
FY2762.7

Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.

Not mentioned in this deck

16
By businessWhat movedCapital spendingShare buybackDividendSelf-rating against planForecast assumptionsRisks priced into the forecastMid-term plan targetsA stated financial targetOrders and backlogPrice and volumeStore or site countHeadcountMarket size and shareInvestor Q&A
Materials for the Results Briefing for the Second Quarter of the Fiscal Year Ending March 2027 | Perseus Proteomics Inc. (4882) timely disclosure | Komori